Company / EPS (Diluted)
ADMA Biologics, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.13
FY2025
5-year range
-$0.88 / -$0.13
FY2021-FY2025
Trend
+60.6%
vs FY2024
Sector context
#53 of 204
Health Care
What the data says
At $-0.13, ADMA Biologics, Inc.'s eps (diluted) ranks #53 of 204 in the Health Care sector. Improved from $-0.51 to $-0.13 over the past 2 years.
Based on SEC 10-K filings.
-0.13 in FY2025.
Improved from $-0.51 to $-0.13 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#53 of 204 in Health CareTop 26% of 204This company -$0.13 Sector average -$0.98
▼
+86.7% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 60.6% year-over-year.
- Ranks #53 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.13 | +60.6% |
| FY2024 | -$0.33 | +35.3% |
| FY2023 | -$0.51 | +0.0% |
| FY2022 | -$0.51 | +42.0% |
| FY2021 | -$0.88 | +1.1% |
| FY2020 | -$0.89 | +38.6% |
| FY2019 | -$1.45 | +24.1% |
| FY2018 | -$1.91 | -18.6% |
| FY2017 | -$1.61 | +6.9% |
| FY2016 | -$1.73 | +4.4% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026